文献速递膀胱癌与上尿路尿路上皮癌

软性与数字输尿管镜及增强成像对UTUC诊疗的肿瘤学结局

Flexible fibre optic vs digital ureteroscopy and enhanced vs unenhanced imaging for diagnosis and treatment of upper tract urothelial carcinoma (UTUC): results from the Clinical Research Office of the Endourology Society (CROES)-UTUC registry.
PubMed 文献 · BJU Int · 2021-06-13

基于CROES-UTUC登记研究,比较软性光纤与数字输尿管镜及NBI、Image1-S增强成像对UTUC患者肿瘤学结局的影响。研究纳入401例行输尿管镜患者,发现数字镜未优于光纤镜,增强成像亦未改善总生存和无病生存,提示术者经验与诊疗集中化更为重要。

要点

  • 数字输尿管镜相比光纤镜未显示肿瘤学优势。
  • NBI和Image1-S未改善总生存或无病生存。
  • 应重视术者技能经验并推动UTUC诊疗集中化。

核心结论

  • 数字输尿管镜相比光纤镜未提供任何肿瘤学优势。
  • 图像增强技术相比数字输尿管镜未改善总生存和无病生存。

研究设计与样本

  • CROES-UTUC为国际多中心前瞻性队列研究,来自101个中心、37个国家共2380例患者。
  • 其中401例行输尿管镜,光纤镜186例、数字镜215例。

主要发现

  • 5年总生存率为91.5%,5年无病生存率为66.4%。
  • 光纤镜组平均总生存42个月、数字镜组39个月(P = 0.9);平均无病生存分别为28个月和21个月(P < 0.001)。
  • 在以治疗为目的的输尿管镜患者中,两组总生存(P = 0.9)和无病生存(P = 0.7)无差异。
  • NBI和Image1-S技术未在数字输尿管镜基础上改善总生存或无病生存。
  • 两组术中及术后并发症无差异。

临床怎么用

  • 选择光纤或数字输尿管镜及是否使用增强成像时,不应以肿瘤学结局作为决策依据。
  • 应重视术者技能与经验,并推动UTUC诊疗的集中化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) undergoing kidney-sparing surgery (KSS) with fibre-optic (FO) vs digital (D) ureteroscopy (URS). To evaluate the oncological impact of image-enhancement technologies such as narrow-band imaging (NBI) and Image1-S in patients with UTUC. PATIENTS AND METHODS: The Clinical Research Office of the Endourology Society (CROES)-UTUC registry is an international, multicentre, cohort study prospectively collecting data on patients with UTUC. Patients undergoing flexible FO- or D-URS for diagnostic or diagnostic and treatment purposes were included. Differences between groups in terms of overall survival (OS) and disease-free survival (DFS) were evaluated. RESULTS: The CROES registry included 2380 patients from 101 centres and 37 countries, of whom 401 patients underwent URS (FO-URS 186 and D-URS 215). FO-URS were performed more frequently for diagnostic purposes, while D-URS was peformed when a combined diagnostic and treatment strategy was planned. Intra- and postoperative complications did not differ between the groups. The 5-year OS and DFS rates were 91.5% and 66.4%, respectively. The mean OS was 42 months for patients receiving FO-URS and 39 months for those undergoing D-URS (P = 0.9); the mean DFS was 28 months in the FO-URS group and 21 months in the D-URS group (P < 0.001). In patients who received URS with treatment purposes, there were no differences in OS (P = 0.9) and DFS (P = 0.7). NBI and Image1-S technologies did not improve OS or DFS over D-URS. CONCLUSIONS: D-URS did not provide any oncological advantage over FO-URS. Similarly, no differences in terms of OS and DFS were found when image-enhancement technologies were compared to D-URS. These findings underline the importance of surgeon skills and experience, and reinforce the need for the centralisation of UTUC care.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Soria F, Laguna MP, Roupret M, et al. Flexible fibre optic vs digital ureteroscopy and enhanced vs unenhanced imaging for diagnosis and treatment of upper tract urothelial carcinoma (UTUC): results from the Clinical Research Office of the Endourology Society (CROES)-UTUC registry. BJU Int. 2021. PMID: 34028166. doi:10.1111/bju.15494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。